Press Releases - 2003

	Jerusalem, Israel, March 30, 2004 Teva Initiates Commercialization of Oxycodone 80 Mg
	Jerusalem, Israel, March 22, 2004 Teva Commences Commercial Launch Of Bupropion 150 Mg
	Jerusalem, Israel, March 12, 2004 Teva Announces Approval Of Amoxicillin/Clavulanate Potassium For Oral Suspension
	Jerusalem, Israel, March 8, 2004 Teva Announces Tentative Approval Of Fenofibrate Tablets, 54 Mg, 160 Mg
	Jerusalem, Israel, March 2, 2004 Teva Comments On Biovail Arbitration Claim
	Jerusalem, Israel, February 17, 2004 Teva Reports Record Sales And Net Income For Q4 2003
	Jerusalem, Israel, February 11, 2004 Teva Announces Final Approval Of Benazepril Hcl Tablets, 5 Mg, 10 Mg, 20 Mg, And 40 Mg
	Jerusalem, Israel, February 5, 2004 Teva Announces Exercise Of Over-Allotment Option For Convertible Debentures
	Jerusalem, Israel, February 1, 2004 Teva To Report Fourth Quarter 2003 Financial Results On February 17, 2004
	Jerusalem, Israel, January 31, 2004 Teva Comments On The Court Of Appeals Decision Regarding Moexipril
	Jerusalem, Israel, January 22, 2004 Teva Announces Pricing Of $1 Billion Convertible Debenture Offering
	Jerusalem, Israel, January 22, 2004 Teva Completes Acquisition of Sicor
	Jerusalem, Israel, January 21, 2004 Teva Announces an Offering of Approximately $ 1 Billion of Convertible Debentures
	Jerusalem, Israel and Irvine, California, January 18, 2004 FTC Grants Early Termination of HSR Waiting Period on Teva Sicor Merger
	Jerusalem, Israel, January 6, 2004 Teva Announces Approval Of Metolazone Tablets, 2.5 Mg And 10 Mg
	Jerusalem, Israel, December 19, 2003 Teva Announces Tentative Approval of Terbinafine HCL Tablets
	Jerusalem, Israel, December 12, 2003 Teva Announces Filing of Universal Shelf Registration Statement
	Jerusalem, Israel, December 10, 2003 Teva and Andrx Announce Collaboration on Generic Oral Contraceptive Products
	Jerusalem, Israel, November 25, 2003 Teva Announces Approval of Fosinopril Sodium Tablets 10 Mg, 20 Mg, And 40 Mg
	Jerusalem, Israel, November 23, 2003 Court of Appeals Affirms Teva's Augmentin® Patent Challenge
	Jerusalem, Israel, November 11, 2003 Teva Announces Continued Convertibility of Its Debentures
	Jerusalem, Israel, November 9, 2003 Teva Announces Approval Of Mupirocin Ointment
	Jerusalem, Israel, November 7, 2003 Teva Announces Termination Of Acquisition Discussions With Savient
	Jerusalem, Israel, November 7, 2003 Teva Announces Tentative Approval Of Benazepril Hcl Tablets, 5 Mg, 10 Mg, 20 Mg, And 40 Mg
	Jerusalem, Israel, November 6, 2003 Teva Announces English Court Of Appeal Upholds Lower Court Ruling To Revoke Two Fosamax® Patents
	Jerusalem, Israel, November 3, 2003 Teva Reports Q3 Net Income of $157 Million, Up 63% Eps of $0.53, Up 47% Q3 Sales of $813 Million, Up 29%
	Jerusalem, Israel and Irvine, CA, October 31, 2003 Teva To Acquire Sicor For $3.4 Billion
	Jerusalem, Israel, October 30, 2003 Teva Announces Court Of Appeals Upholds Lower Court Ruling On Daily Version Of Fosamax®
	Jerusalem, Israel, October 27, 2003 Teva Receives Favorable Court Ruling On Fosinopril Sodium Tablets
	Jerusalem, Israel, October 20, 2003 Teva to Report Third Quarter 2003 Financial Results on November 3, 2003
	Jerusalem, Israel, October 17, 2003 Teva Announces Tentative Approval for Gabapentin Tablets, 600 Mg and 800 Mg
	Jerusalem, Israel, October 15, 2003 Teva Announces Conversion Of 1.5% Convertible Debentures Due 2005
	Jerusalem, Israel, October 12, 2003 Teva And Lundbeck Announce European Submission Of Rasagiline As A Treatment For Parkinson's Disease
	Jerusalem, Israel, October 3, 2003 Teva Confirms That It Is In Preliminary Acquisition Discussions With Savient Pharmaceuticals, Inc.
	Jerusalem, Israel, September 30, 2003 Teva Announces Tentative Approval Of Oxycodone Hydrochloride ER Tablets, 80 Mg
	Jerusalem, Israel, September 25, 2003 Teva Calls 1.5% Convertible Debentures Due 2005 For Redemption
	Jerusalem, Israel, September 25, 2003 Massachusetts Attorney General To Bring Action Against 13 Generic Drug Companies For Pricing Practices
	JERUSALEM, ISRAEL, September 25, 2003 Teva And Aventis Announce That All Relapsing Remitting Multiple Sclerosis Patients in France Will Now Have Access to Copaxone®
	Jerusalem, Israel, and Hawthorne, NY, September 23, 2003, September 23, 2003 Teva and Acorda Therapeutics Agree to Co-Develop and Co-Promote Valrocemide in The U.S.
	Jerusalem, Israel, September 16, 2003 Teva Announces Approval of Nefazodone HCl Tablets 50 mg, 100 mg, 150 mg, 200 mg and 250 mg
	Jerusalem, Israel, September 8, 2003 Teva Announces NDA Submission of Rasagiline as a Treatment for Parkinson's Disease
	Jerusalem, Israel, September 2, 2003 Teva Announces Approval of Ofloxacin Tablets 200 mg, 300 mg, and 400 mg
	Jerusalem, Israel, August 29, 2003 Teva to Appeal Lower Court Ruling on Weekly Version of FOSAMAX®
	Jerusalem, Israel, August 7, 2003 Teva Announces Tentative Approval for Gabapentin Capsules
	Jerusalem, Israel, August 5, 2003 Teva Announces Conversion Period for Debentures
	Jerusalem, Israel, July 31, 2003 Teva Signs Agreement With Andrx and Impax for Generic Formulations of Wellbutrin® Sr and Zyban®
	Jerusalem, Israel, July 29, 2003 Teva Improves Outlook for Full Year 2003
	Jerusalem, Israel, July 29, 2003 Teva Reports Q2 EPS of $0.75 Including One Time Items$0.49 Before One Time Items - an Increase of 44% Q2 Sales Increased 34% to $764 Million
	Jerusalem, Israel, July 16, 2003 Teva Announces District Court Grants Motion for Summary Judgment of Non-Infringement of All Ribapharm Patents Related to Rebetol®
	Jerusalem, Israel, July 10, 2003 Teva Announces Tentative Approval of Fosinopril Sodium Tablets
	Jerusalem, Israel, July 10, 2003 Teva to Report Second Quarter 2003 Financial Results on July 29, 2003
	Jerusalem, Israel, July 1, 2003 Teva Receives North American Rights to Purinethol® as Part of Glaxosmithkline Settlement
	Jerusalem, Israel, June 19, 2003 Teva Announces Approval of Mirtazapine Tablets, 45 mg
	Jerusalem, Israel, June 2, 2003 Teva Announces Final Approval for Quinapril Hydrochloride Tablets
	Jerusalem, Israel and Tokyo, Japan, May 15, 2003 Teva and Eisai Sign Agreement for Co-Development of Rasagiline for Alzheimer's Disease, and Co-Promotion for Parkinson's Disease, in the U.S.
	Jerusalem, Israel, May 8, 2003 Teva Announces Approval of Moexipril HCl Tablets
	Jerusalem, Israel, May 6, 2003 Teva Announces Approval of Megestrol Acetate Oral Suspension
	Jerusalem, Israel, April 30, 2003 Teva Announces Settlement of Litigation with GSK on Nabumetone
	Jerusalem, Israel, April 21, 2003 Teva to Report First Quarter 2003 Financial Results on May 1, 2003
	Jerusalem, Israel, April 14, 2003 Teva Announces Approval of Hydrocodone Bitartrate and Ibuprofen Tablets
	Jerusalem, Israel, March 26, 2003 Teva and Schering-Plough Enter into License Agreement Covering Schering-Plough’s Ribavirin Patents
	Jerusalem, Israel, March 26, 2003 Teva & Lundbeck Announce Successful Completion of Rasagiline Phase III Clinical Program in Parkinson’s Disease
	Jerusalem, Israel, March 26, 2003 Teva Announces Tentative Approval of Metformin HCl Extended-Release Tablets
	Jerusalem, Israel, February 21, 2003 Teva Announces Final Approval of Tamoxifen Citrate Tablets
	Jerusalem, Israel, February 18, 2003 Teva Reports Record Sales and Earnings 2002 Sales Exceed $ 2.5 Billion Full Year EPS of $1.52, Up 43% Increase of 50% in Dividend for Q4, 2002
	Jerusalem, Israel, January 27, 2003 Teva to Report Fourth Quarter 2002 Financial Results on February 18, 2003;
	Jerusalem, Israel, January 27, 2003 Teva to Present at U.S. Bancorp Piper Jaffray Health Care Conference
	Jerusalem, Israel, January 24, 2003 Teva Announces Final Approval of Mirtazapine 15mg, 30mg 180-day Marketing Exclusivity
	Jerusalem, Israel, January 21, 2003 Teva Announces U.K. High Court Revokes Two Fosamax ® Patents
	Jerusalem, Israel, January 15, 2003 Teva Announces Tentative Approval of Carboplatin Injection
	Jerusalem, Israel, January 14, 2003 Teva Clarifies Media Reports Regarding Rasagiline Status
	Jerusalem, Israel, January 6, 2003 Teva & Lundbeck Announce Phase III Trials Did Not Demonstrate Etilevodopa Superiority Over Standard Levodopa